Tusk Therapeutics Overview

  • Founded
  • 2015

Founded
  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $764M

Tusk Therapeutics General Information

Description

Developer of an innate immune system designed to harness the power of the immune system for the treatment of cancer. The company's system is developing novel immune modulating therapeutics based on an in-depth understanding of the innate immune system with a special focus on Natural Killer (NK) cell biology, enabling cancer patients to get full recovery.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Therapeutic Devices
Acquirer
Primary Office
  • Stevenage Bioscience Catalyst
  • Gunnels Wood Road, Stevenage
  • Hertfordshire SG1 2FX
  • England, United Kingdom

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tusk Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 27-Sep-2018 $764M 00000 Completed Pre-Clinical Trials
3. Grant 14-Nov-2017 00.000 Completed Pre-Clinical Trials
2. Early Stage VC Completed Startup
1. Accelerator/Incubator Completed Startup
To view Tusk Therapeutics’s complete valuation and funding history, request access »

Tusk Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of an innate immune system designed to harness the power of the immune system for the treatment of cancer. The
Biotechnology
Hertfordshire, United Kingdom
0000 0000-00-00
000000&0

000000

Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo con
0000 000000000
Vienna, Austria
00 As of 0000
000.00
0000000000 0

000000

or incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation u
0000000000000
Cambridge, MA
0 As of 0000
0000 0000-00-00
0000000000 0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tusk Therapeutics Competitors (39)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
APEIRON Biologics Venture Capital-Backed Vienna, Austria 00 000.00 0000000000 0
0000000 Venture Capital-Backed Cambridge, MA 0 0000000000 0
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
0000 000000000000 Formerly VC-backed San Diego, CA 000 00000 00000000 00000
0000 000000 Formerly VC-backed Santa Monica, CA 000 00000 000000&0 00000
You’re viewing 5 of 39 competitors. Get the full list »

Tusk Therapeutics Patents

Tusk Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2019233575-A1 Anti-cd25 for tumour specific cell depletion Pending 13-Mar-2018 00000000000
AU-2019233576-A1 Anti-cd25 for tumour specific cell depletion Pending 13-Mar-2018 00000000000
US-10745485-B2 Anti-cd25 antibody agents Active 13-Mar-2018 00000000000 00
US-20210040221-A1 Anti-cd25 for tumour specific cell depletion Pending 13-Mar-2018 00000000000
US-20190284287-A1 Anti-cd25 antibody agents Granted 13-Mar-2018 C07K16/2818
To view Tusk Therapeutics’s complete patent history, request access »

Tusk Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Pascal Merchiers Ph.D Vice President of Research & Development
Dominic Smethurst Chief Medical Officer
You’re viewing 2 of 5 executive team members. Get the full list »

Tusk Therapeutics Board Members (6)

Name Representing Role Since
Eric Rowinsky Tusk Therapeutics Board Member 000 0000
You’re viewing 1 of 6 board members. Get the full list »

Tusk Therapeutics Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Droia Oncology Ventures Venture Capital Minority 000 0000 000000 0
Innovate UK Government 000 0000 000000 0
Stevenage Bioscience Catalyst Accelerator/Incubator Minority 000 0000 000000 0
To view Tusk Therapeutics’s complete investors history, request access »